Tirzepatide

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

A Case Report of Systemic Allergic Reaction to the Dual Glucose-Dependent Insulinotropic Polypeptide/Glucagon-Like Peptide-1 Receptor Agonist Tirzepatide

“…Allergic and hypersensitivity reactions were observed in 1% to 2% of tirzepatide-treated patients, slightly higher than the 1% incidence in placebo recipients. Importantly, patients with treatment-emergent antidrug antibodies to tirzepatide did not report severe or serious hypersensitivity or injection-site reactions, although detailed data on this were not disclosed [ 20 ].…”

In-Home Management of Diabetes and Obesity

“…Although GLP-1 RA medications have been utilized for diabetes management for years, semaglutide and liraglutide have been recently approved by the Food and Drug Administration (FDA) for weight loss (FDA, 2020, 2021). Tirzepatide is a dual GLP-1 RA and glucose-dependent insulinotropic polypeptide, which increases glucagon production and impacts blood lipids resulting in improved beta cell function and insulin sensitivity (Baker et al, 2023). Two GLP-1 RA medications are available at the time of this writing that are combined with a fixed dose of a basal insulin with once-daily dosing: insulin glargine with lixisenatide (Soliqua©); insulin degludec with liraglutide (Xultophy©) (ElSayed, Aleppo, Aroda, Bannuru, Brown, Bruemmer, Collins, Hilliard, et al, 2023).…”

“…GLP-1 RA medications are contraindicated in patients with hypersensitivity reactions; personal or family history of multiple endocrine neoplasia or medullary thyroid cancer; and caution should be used in patients with a history of pancreatitis, gastroparesis, or inflammatory bowel disease (Collins & Costello, 2023). GLP-1 RA medications are not recommended in pregnancy, and it is advised that patients using hormonal contraceptives use alternative contraception for 4 weeks after drug initiation and dosage increases (Baker et al, 2023).…”

A Comprehensive Review on Weight Loss Associated with Anti-Diabetic Medications

“…As a subcutaneous injection, it is given once per week [207]. Tirzepatide has been shown to be effective in the treatment of non-alcoholic steatohepatitis, T2DM, and overweight and obese patients independent of their diabetes status [207,209]. Clinical trials known as the SURPASS clinical trials were used to examine the efficacy and safety of tirzepatide [209][210][211][212][213].…”

“…Tirzepatide has been shown to be effective in the treatment of non-alcoholic steatohepatitis, T2DM, and overweight and obese patients independent of their diabetes status [207,209]. Clinical trials known as the SURPASS clinical trials were used to examine the efficacy and safety of tirzepatide [209][210][211][212][213]. The tirzepatide weight loss effects from the SURPASS clinical trials are summarized in this study [210][211][212][213].…”